SOM Biotech 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
prexasertib (ACR-368) / Acrivon Therap
ExIST, NCT04032080: LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

Completed
2
10
US
Drug 1: LY3023414; Drug 2: Prexasertib
Baylor Research Institute, Eli Lilly and Company
Triple Negative Breast Cancer
06/22
11/22
NCT06597565: A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Recruiting
2
43
US
Gemcitabine, ACR-368, Prexasertib
H. Lee Moffitt Cancer Center and Research Institute, Acrivon Therapeutics
Head and Neck Squamous Cell Carcinoma
08/28
08/28
NCT04095221: A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Completed
1/2
21
US
Prexasertib, Irinotecan
Memorial Sloan Kettering Cancer Center
Desmoplastic Small Round Cell Tumor, Rhabdomyosarcoma
02/25
02/25
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
St. Jude ELIOT, NCT04023669: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Completed
1
21
US
Prexasertib, LY2606368, Cyclophosphamide, Cytoxan, Gemcitabine, 2'-deoxy-2',2' difluorocytidine monohydrochloride, LY18801, Gemzar®, filgrastim, G-CSF, peg-filgrastim, pegylated filgrastim, PEG filgrastim, Neulasta®
St. Jude Children's Research Hospital, Eli Lilly and Company
Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
05/23
01/25
Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
TheraCRAB, NCT06440304: Therapeutic Options for CRAB

Recruiting
4
108
RoW
Fosfomycin, Fosfomycin with Colistin, Eravacycline, Eravacycline with Colistin, ampicillin/sulbactam, Ampicilin/sulbactam with Colistin
Clinical Hospital Centre Zagreb
Infections, Bacterial, Sepsis Bacterial
12/26
02/27
TREAT-GNB, NCT07004049: Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting
4
600
Europe, RoW
Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem, Ceftazidime-avibactam + Sulbactam, Ceftazidime-avibactam + Fosfomycin, Ceftazidime-avibactam, Ceftazidime-avibactam + Aztreonam, Ceftazidime-avibactam + Colistin/Polymyxin B, High-dose meropenem, Meropenem + Fosfomycin, Meropenem-vaborbactam, Cefiderocol, Ceftolozane-tazobactam, Ceftolozane-tazobactam + Meropenem
National University of Singapore, The University of Queensland, European Clinical Research Alliance for Infectious Diseases (ECRAID)
Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection, Multidrug Resistance
12/28
12/28
ChiCTR2400087137: A study on the pharmacokinetic characteristics and penetration of Eravacycline in the pulmonary bronchial fluid of adult patients with hospital-acquired pneumonia or ventilator-associated pneumonia

Not yet recruiting
4
16
 
Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Funded by Everest Medicines for this IIT study
HAP or VAP
 
 
ChiCTR2500098643: An exploratory study on the efficacy of eravacycline in CRKP infection

Not yet recruiting
4
60
 
Elacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazobactam, piperac; Tigacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazo
Shanghai tenth People's Hospital; Shanghai tenth People's Hospital, Self-funded project
Intraperitoneal infection, bloodstream infection, pulmonary infection, urinary infection
 
 
ChiCTR1900022060: A Phase 3, Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Ertapenem in the Treatment of Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Adults

Completed
3
160
 
Eravacycline 1.0 mg/kg IV q 12h ;Ertapenem 1g IV q 24h
West China Hospital, Sichuan University; Everest Medicines (US) Limited, Fully founded by sponsor
Complicated intra-abdominal infections
 
 
ChiCTR2300078646: Efficacy and safety of eravacycline for complicated intra-abdominal infections in the ICU: A multicenter, single-blind, parallel randomized controlled trial study

Recruiting
3
292
 
Intravenous eravacycline; Intravenous tigecycline
Ansteel Group General Hospital; Ansteel Group General Hospital, Health Development Promotion Project of Beijing Health Alliance Charitable Foundation
Complicated intra-abdominal infections
 
 
ChiCTR2200055666: A Phase II/III, Randomized, Two-stage Clinical Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Moxifloxacin in the Treatment of Community-acquired Bacterial Pneumonia (CABP) in Adult Subjects

Recruiting
2/3
520
 
Elacycline 1.0 mg/kg IV q 12 h ;Two doses of eracycline 1.5 mg/kg IV were administered 12 hours apart (q12h). From the second day to the end of treatment (the third dose to the final dose), elacycline was 1.5 mg/kg, q24h ;Elacycline (dose and frequency determined in Stage 1) ;Moxifloxacin 0.4 g IV q24h
China-Japan Friendship Hospital; Everest Medicines (US) Limited, self-funded
Community-acquired Bacterial Pneumonia
 
 
NCT06794541: A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Recruiting
2
35
US
Eravacycline 2mg/kg, Eravacycline 1.5mg/kg
Innoviva Specialty Therapeutics, Tetraphase Pharmaceuticals, Inc.
Complicated Intra-abdominal Infections (cIAI)
03/29
03/29
NCT05537896: Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting
2
55
US
Eravacycline, Xerava
West Virginia University
Hematological Malignancy, Neutropenia
02/28
02/28
ChiCTR1900022906: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose and Multiple-dose Intravenous Infusion of Eraracycline in Chinese Healthy Subjects

Completed
1
28
 
Eravacycline 0.5 mg/kg IV single dose ;Single dose: Eravacycline 1 mg/kg IV; Multiple dose: Eravacycline 1 mg/kg IV q12h, 10 days ;Eravacycline 2 mg/kg IV single dose
Huashan Hospital Affiliated to Fudan University; Everest Medicines (US) Limited, Fully founded by sponsor
Not applicable
 
 
NCT06282835: Eravacycline Combination Therapy for MRAB

Recruiting
N/A
20
RoW
Eravacycline Injection
Fujian Medical University Union Hospital
Pulmonary Infection, Pneumonia, Bacterial, Acinetobacter Baumannii
10/24
12/24
NCT06223100: Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

Not yet recruiting
N/A
100
NA
Eravacycline, XERAVA
Sichuan Provincial People's Hospital
Immune Dysregulation Disorder
12/25
12/25
NCT06670872: A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia

Not yet recruiting
N/A
50
RoW
Eravacycline combination therapy group
Peking University Third Hospital
Pneumonitis, Acinetobacter Baumannii
10/25
10/26
NCT06666998: Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients

Not yet recruiting
N/A
100
NA
Sichuan Provincial People's Hospital
Eravacycline, Pharmacokinetics, Bacteria Infection, Bacterial Resistance to Antimicrobial, Empirical Antimicrobial Therapy
11/26
11/26
ChiCTR2400089338: The efficacy and safety observation study of Eravacycline treatment in patients with neutropenia and fever: A multicenter retrospective cohort study based on HIS data

Not yet recruiting
N/A
200
 
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Life Oasis Public Service Center
Granulocyte deficiency with fever
 
 
ChiCTR2400083038: A real-world study of the clinical use of eravacycline

Recruiting
N/A
50
 
None
Huashan hospital; Huashan hospital, Beijing Life Oasis public Service Center
Bacterial Infection
 
 
ChiCTR2500103344: Retrospective Study on the Efficacy and Safety of Eravacycline Based on Real-world Data

Not yet recruiting
N/A
300
 
NA
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, None
Patients clinically diagnosed with infections (including pulmonary infections, skin/soft tissue infections, intra-abdominal infections, bloodstream infections, etc.).
 
 
ChiCTR2500096976: Synergistic Mechanisms of Eravacycline Combined with Aminoglycosides in the Treatment of CRE Infections: A Single-Arm Clinical Study and Integrated Multi-Omics Analysis

Not yet recruiting
N/A
9
 
SUN YAT-SEN MEMORIAL HOSPITAL; SUN YAT-SEN MEMORIAL HOSPITAL, Primary Health Care Foundation of China
CRE infection
 
 
bevantolol (SOM3355) / SOM Biotech
2021-003453-28: Phase IIb study assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with choreic movements. Estudio de Fase IIb para evaluar la eficacia y la seguridad de dos dosis de SOM3355 en pacientes con Enfermedad de Huntington con movimientos coreicos.

Not yet recruiting
2
129
Europe
SOM3355 (bevantolol hydrochloride), SOM3355, Capsule, Calvan (bevantolol hydrochloride)
SOM Innovation Biotech SA (SOM Biotech), SOM Innovation Biotech S.A., SOM Innovation Biotech SA (SOM Biotech)
Huntington’s Disease with choreic movements. Enfermedad de Huntington con movimientos coreicos., Huntington’s Disease with choreic movements. Enfermedad de Huntington con movimientos coreicos., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05475483 / 2021-003453-28: Efficacy and Safety on SOM3355 in Huntington's Disease Chorea

Completed
2
140
Europe
SOM3355 capsules, Bevantolol hydrochloride, Placebo capsules
SOM Innovation Biotech SA, SOM Innovation Biotech SA (SOM Biotech)
Huntington Chorea
06/24
07/24
tolcapone (CRX-1008) / Corino Therap, SOM Biotech
No trials found
SOM2201 / SOM Biotech
No trials found
cynarine / Ewha Womans University, SOM Biotech
No trials found
SOM0777 / U-Cell Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
prexasertib (ACR-368) / Acrivon Therap
ExIST, NCT04032080: LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

Completed
2
10
US
Drug 1: LY3023414; Drug 2: Prexasertib
Baylor Research Institute, Eli Lilly and Company
Triple Negative Breast Cancer
06/22
11/22
NCT06597565: A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Recruiting
2
43
US
Gemcitabine, ACR-368, Prexasertib
H. Lee Moffitt Cancer Center and Research Institute, Acrivon Therapeutics
Head and Neck Squamous Cell Carcinoma
08/28
08/28
NCT04095221: A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Completed
1/2
21
US
Prexasertib, Irinotecan
Memorial Sloan Kettering Cancer Center
Desmoplastic Small Round Cell Tumor, Rhabdomyosarcoma
02/25
02/25
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
St. Jude ELIOT, NCT04023669: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Completed
1
21
US
Prexasertib, LY2606368, Cyclophosphamide, Cytoxan, Gemcitabine, 2'-deoxy-2',2' difluorocytidine monohydrochloride, LY18801, Gemzar®, filgrastim, G-CSF, peg-filgrastim, pegylated filgrastim, PEG filgrastim, Neulasta®
St. Jude Children's Research Hospital, Eli Lilly and Company
Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
05/23
01/25
Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
TheraCRAB, NCT06440304: Therapeutic Options for CRAB

Recruiting
4
108
RoW
Fosfomycin, Fosfomycin with Colistin, Eravacycline, Eravacycline with Colistin, ampicillin/sulbactam, Ampicilin/sulbactam with Colistin
Clinical Hospital Centre Zagreb
Infections, Bacterial, Sepsis Bacterial
12/26
02/27
TREAT-GNB, NCT07004049: Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting
4
600
Europe, RoW
Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem, Ceftazidime-avibactam + Sulbactam, Ceftazidime-avibactam + Fosfomycin, Ceftazidime-avibactam, Ceftazidime-avibactam + Aztreonam, Ceftazidime-avibactam + Colistin/Polymyxin B, High-dose meropenem, Meropenem + Fosfomycin, Meropenem-vaborbactam, Cefiderocol, Ceftolozane-tazobactam, Ceftolozane-tazobactam + Meropenem
National University of Singapore, The University of Queensland, European Clinical Research Alliance for Infectious Diseases (ECRAID)
Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection, Multidrug Resistance
12/28
12/28
ChiCTR2400087137: A study on the pharmacokinetic characteristics and penetration of Eravacycline in the pulmonary bronchial fluid of adult patients with hospital-acquired pneumonia or ventilator-associated pneumonia

Not yet recruiting
4
16
 
Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Funded by Everest Medicines for this IIT study
HAP or VAP
 
 
ChiCTR2500098643: An exploratory study on the efficacy of eravacycline in CRKP infection

Not yet recruiting
4
60
 
Elacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazobactam, piperac; Tigacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazo
Shanghai tenth People's Hospital; Shanghai tenth People's Hospital, Self-funded project
Intraperitoneal infection, bloodstream infection, pulmonary infection, urinary infection
 
 
ChiCTR1900022060: A Phase 3, Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Ertapenem in the Treatment of Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Adults

Completed
3
160
 
Eravacycline 1.0 mg/kg IV q 12h ;Ertapenem 1g IV q 24h
West China Hospital, Sichuan University; Everest Medicines (US) Limited, Fully founded by sponsor
Complicated intra-abdominal infections
 
 
ChiCTR2300078646: Efficacy and safety of eravacycline for complicated intra-abdominal infections in the ICU: A multicenter, single-blind, parallel randomized controlled trial study

Recruiting
3
292
 
Intravenous eravacycline; Intravenous tigecycline
Ansteel Group General Hospital; Ansteel Group General Hospital, Health Development Promotion Project of Beijing Health Alliance Charitable Foundation
Complicated intra-abdominal infections
 
 
ChiCTR2200055666: A Phase II/III, Randomized, Two-stage Clinical Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Moxifloxacin in the Treatment of Community-acquired Bacterial Pneumonia (CABP) in Adult Subjects

Recruiting
2/3
520
 
Elacycline 1.0 mg/kg IV q 12 h ;Two doses of eracycline 1.5 mg/kg IV were administered 12 hours apart (q12h). From the second day to the end of treatment (the third dose to the final dose), elacycline was 1.5 mg/kg, q24h ;Elacycline (dose and frequency determined in Stage 1) ;Moxifloxacin 0.4 g IV q24h
China-Japan Friendship Hospital; Everest Medicines (US) Limited, self-funded
Community-acquired Bacterial Pneumonia
 
 
NCT06794541: A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Recruiting
2
35
US
Eravacycline 2mg/kg, Eravacycline 1.5mg/kg
Innoviva Specialty Therapeutics, Tetraphase Pharmaceuticals, Inc.
Complicated Intra-abdominal Infections (cIAI)
03/29
03/29
NCT05537896: Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting
2
55
US
Eravacycline, Xerava
West Virginia University
Hematological Malignancy, Neutropenia
02/28
02/28
ChiCTR1900022906: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose and Multiple-dose Intravenous Infusion of Eraracycline in Chinese Healthy Subjects

Completed
1
28
 
Eravacycline 0.5 mg/kg IV single dose ;Single dose: Eravacycline 1 mg/kg IV; Multiple dose: Eravacycline 1 mg/kg IV q12h, 10 days ;Eravacycline 2 mg/kg IV single dose
Huashan Hospital Affiliated to Fudan University; Everest Medicines (US) Limited, Fully founded by sponsor
Not applicable
 
 
NCT06282835: Eravacycline Combination Therapy for MRAB

Recruiting
N/A
20
RoW
Eravacycline Injection
Fujian Medical University Union Hospital
Pulmonary Infection, Pneumonia, Bacterial, Acinetobacter Baumannii
10/24
12/24
NCT06223100: Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

Not yet recruiting
N/A
100
NA
Eravacycline, XERAVA
Sichuan Provincial People's Hospital
Immune Dysregulation Disorder
12/25
12/25
NCT06670872: A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia

Not yet recruiting
N/A
50
RoW
Eravacycline combination therapy group
Peking University Third Hospital
Pneumonitis, Acinetobacter Baumannii
10/25
10/26
NCT06666998: Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients

Not yet recruiting
N/A
100
NA
Sichuan Provincial People's Hospital
Eravacycline, Pharmacokinetics, Bacteria Infection, Bacterial Resistance to Antimicrobial, Empirical Antimicrobial Therapy
11/26
11/26
ChiCTR2400089338: The efficacy and safety observation study of Eravacycline treatment in patients with neutropenia and fever: A multicenter retrospective cohort study based on HIS data

Not yet recruiting
N/A
200
 
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Life Oasis Public Service Center
Granulocyte deficiency with fever
 
 
ChiCTR2400083038: A real-world study of the clinical use of eravacycline

Recruiting
N/A
50
 
None
Huashan hospital; Huashan hospital, Beijing Life Oasis public Service Center
Bacterial Infection
 
 
ChiCTR2500103344: Retrospective Study on the Efficacy and Safety of Eravacycline Based on Real-world Data

Not yet recruiting
N/A
300
 
NA
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, None
Patients clinically diagnosed with infections (including pulmonary infections, skin/soft tissue infections, intra-abdominal infections, bloodstream infections, etc.).
 
 
ChiCTR2500096976: Synergistic Mechanisms of Eravacycline Combined with Aminoglycosides in the Treatment of CRE Infections: A Single-Arm Clinical Study and Integrated Multi-Omics Analysis

Not yet recruiting
N/A
9
 
SUN YAT-SEN MEMORIAL HOSPITAL; SUN YAT-SEN MEMORIAL HOSPITAL, Primary Health Care Foundation of China
CRE infection
 
 
bevantolol (SOM3355) / SOM Biotech
2021-003453-28: Phase IIb study assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with choreic movements. Estudio de Fase IIb para evaluar la eficacia y la seguridad de dos dosis de SOM3355 en pacientes con Enfermedad de Huntington con movimientos coreicos.

Not yet recruiting
2
129
Europe
SOM3355 (bevantolol hydrochloride), SOM3355, Capsule, Calvan (bevantolol hydrochloride)
SOM Innovation Biotech SA (SOM Biotech), SOM Innovation Biotech S.A., SOM Innovation Biotech SA (SOM Biotech)
Huntington’s Disease with choreic movements. Enfermedad de Huntington con movimientos coreicos., Huntington’s Disease with choreic movements. Enfermedad de Huntington con movimientos coreicos., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05475483 / 2021-003453-28: Efficacy and Safety on SOM3355 in Huntington's Disease Chorea

Completed
2
140
Europe
SOM3355 capsules, Bevantolol hydrochloride, Placebo capsules
SOM Innovation Biotech SA, SOM Innovation Biotech SA (SOM Biotech)
Huntington Chorea
06/24
07/24
tolcapone (CRX-1008) / Corino Therap, SOM Biotech
No trials found
SOM2201 / SOM Biotech
No trials found
cynarine / Ewha Womans University, SOM Biotech
No trials found
SOM0777 / U-Cell Therap
No trials found

Download Options